Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438 | Active Not Recruiting Phase 2 FDA Drug

• 1 other identifier: CL-QRX003-001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 5

Brief Summary

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

Conditions

Netherton Syndrome

Outcome Measures

Primary Outcomes (9)

• Efficacy Endpoints-1-point IGA

  Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

  Up to week 16

• Efficacy Endpoints-2-point IGA

  Proportion of subjects with 2-point reduction in IGA from Baseline.

  Up to week 16

• Efficacy Endpoints-NS Sign

  Change from Baseline in each individual NS Sign (erythema and scaling). Severity of each NS sign is graded on a 5-point scale.

  Up to week 16

• Efficacy Endpoints-BSA

  Change from Baseline in total Body Surface Area (BSA) affected by NS in the Treatment Area

  Up to week 16

• Efficacy Endpoints-WI-NRS score

  Change from Baseline in the Worst Itch-Numeric Rating Scale (WI-NRS) score. Itch severity is graded on an 11-point scale where 0 represents "no itch" and 10 represents "worst itch imaginable".

  Up to week 16

• Efficacy Endpoints-TSQM

  Assessment of subject satisfaction with treatment based on the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM measures a subject's level of satisfaction or dissatisfaction with the treatment. Composite scores can range from 0 to 100; higher scores indicate better satisfaction.

  Up to week 16

• Efficacy Endpoints-Rescue Therapy

  Proportion of subjects requiring rescue therapy

  Up to week 16

• Safety Endpoints-AEs

  Any local and systemic AEs (Adverse Events)/serious AEs

  Up to week 16

• Safety Endpoints-LSR

  Number of subjects with presence of the following LSRs (Local Skin Reactions): edema, excoriations, oozing/vesiculation/crusting, and erosions at any study visit.

  Up to week 16

Study Arms (4)

QRX003-2% QAM

EXPERIMENTAL

Subjects will apply test article once daily in the morning (QAM) for 12 weeks

Drug: QRX003-2% Lotion

QRX003-4% QAM

EXPERIMENTAL

Subjects will apply test article once daily in the morning (QAM) for 12 weeks

Drug: QRX003-4% Lotion QAM

Vehicle Lotion

EXPERIMENTAL

Subjects will apply test article once daily in the morning (QAM) for 12 weeks

Drug: Vehicle

QRX003-4% BID

EXPERIMENTAL

Subjects will apply test article twice daily BID for 12 weeks

Drug: QRX003-4% Lotion BID

Interventions

QRX003-4% Lotion QAM DRUG

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

QRX003-4% QAM

Vehicle DRUG

Vehicle Lotion

Vehicle Lotion

QRX003-4% Lotion BID DRUG

QRX003Topical Lotion containing 4% active drug (serine protease inhibitor)

QRX003-4% BID

QRX003-2% Lotion DRUG

QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)

QRX003-2% QAM

Eligibility Criteria

• Age: 14 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject is a male or non-pregnant female at least 14 years of age.
• Females must be post-menopausal , surgically sterile , or use an effective method of birth control , for the duration of the study and for 3 months following completion of treatment. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline.
• Subject has a clinical diagnosis of NS and agrees to genetic testing at Visit 1/Screening for confirmation of NS diagnosis if the subject does not have test results confirming a SPINK5 mutation.
• Subject has NS lesions in the Treatment Area (i.e., arms or lower legs).
• Subject is in good general health and free of any disease state or physical condition that might impair evaluation of NS or exposes the subject to an unacceptable risk by study participation.

You may not qualify if:

• Subject is pregnant, lactating, or is planning to become pregnant during the study.
• Subject has any skin pathology in the Treatment Area or condition that, could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy.
• Subject has Fridericia-corrected QT ≥ 450 ms for males or ≥ 470 ms for females
• Subject has active cancer of any type excluding non-melanoma skin cancer outside of the Treatment Area.
• Subject has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled.
• Subject has evidence of active infection during screening, or serious infection within 30 days prior to Visit 2/Baseline.
• Subject has known human immunodeficiency virus, hepatitis B or C virus, or active or latent tuberculosis.
• Subject has used ultraviolet phototherapy within the Treatment Area within 4 weeks prior to Visit 2/Baseline.
• Subject has used systemic prescription treatment for NS within 4 weeks prior to Visit 2/Baseline.
• Subject has used systemic biologic therapy for NS.
• Subject has used topical prescription treatment in the Treatment Area within 2 weeks prior to Visit 2/Baseline.
• Subject has used any topical bland moisturizers/emollients in the Treatment Area within 24 hours prior to Visit 2/Baseline.
• Subject is currently enrolled in an investigational drug, biologic, or device study.
• Subject has used an investigational drug, biologic, or device treatment within 30 days prior to Visit 2/Baseline.

Sponsors & Collaborators

• Quoin Pharmaceuticals: lead

Study Sites (5)

Site #1

San Diego, California, 92123, United States

Location

Site #4

Indianapolis, Indiana, 46250, United States

Location

Site #5

Quincy, Massachusetts, 02169, United States

Location

Site #3

Charleston, South Carolina, 29425, United States

Location

Site #2

San Antonio, Texas, 72218, United States

Location

MeSH Terms

Conditions

Netherton Syndrome

Condition Hierarchy (Ancestors)

Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Ichthyosiform Erythroderma, Congenital; Ichthyosis; Skin Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Infant, Newborn, Diseases; Keratosis; Skin Diseases; Skin and Connective Tissue Diseases

Study Officials

• Tony Andrasfay

  Therapeutics, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Masking Details: Double-blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 17, 2022
• First Posted: August 30, 2022
• Study Start: June 23, 2022
• Primary Completion: December 30, 2025
• Study Completion (Estimated): December 31, 2026
• Last Updated: March 16, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (5)